WO2005046575A3 - Amino acid prodrugs - Google Patents

Amino acid prodrugs Download PDF

Info

Publication number
WO2005046575A3
WO2005046575A3 PCT/US2004/024901 US2004024901W WO2005046575A3 WO 2005046575 A3 WO2005046575 A3 WO 2005046575A3 US 2004024901 W US2004024901 W US 2004024901W WO 2005046575 A3 WO2005046575 A3 WO 2005046575A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
amino acid
present invention
drug
directed
prodrug
Prior art date
Application number
PCT/US2004/024901
Other languages
French (fr)
Other versions
WO2005046575A2 (en )
Inventor
V Ravi Chandran
Original Assignee
Signature R & D Holdings Lcc
V Ravi Chandran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria

Abstract

The present invention is directed to a prodrug comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The prodrug has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the prodrugs of the present invention enhance at least two therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.
PCT/US2004/024901 2003-07-29 2004-07-29 Amino acid prodrugs WO2005046575A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US49133103 true 2003-07-29 2003-07-29
US60/491,331 2003-07-29

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
KR20137015399A KR20130081319A (en) 2003-07-29 2004-07-29 Amino acid prodrugs
CA 2534342 CA2534342C (en) 2003-07-29 2004-07-29 Amino acid prodrugs
JP2006522125A JP2007510621A (en) 2003-07-29 2004-07-29 Amino acid prodrugs
EP20040816791 EP1660017A4 (en) 2003-07-29 2004-07-29 Amino acid prodrugs
US11343557 US8173840B2 (en) 2003-07-29 2006-01-30 Compounds with high therapeutic index
US11442027 US7589233B2 (en) 2003-07-29 2006-05-26 L-Threonine derivatives of high therapeutic index
US12557080 US20100069489A1 (en) 2003-07-29 2009-09-10 L-threonine derivatives of high therapeutic index
US12557030 US8188311B2 (en) 2003-07-29 2009-09-10 L-threonine derivatives of high therapeutic index
US12556968 US8563776B2 (en) 2003-07-29 2009-09-10 L-Threonine derivatives of high therapeutic index
US13449791 US20120289471A1 (en) 2003-07-29 2012-04-18 Novel compounds with high therapeutic index

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11343557 Continuation-In-Part US8173840B2 (en) 2003-07-29 2006-01-30 Compounds with high therapeutic index

Publications (2)

Publication Number Publication Date
WO2005046575A2 true WO2005046575A2 (en) 2005-05-26
WO2005046575A3 true true WO2005046575A3 (en) 2007-10-04

Family

ID=34590076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024901 WO2005046575A3 (en) 2003-07-29 2004-07-29 Amino acid prodrugs

Country Status (6)

Country Link
EP (1) EP1660017A4 (en)
JP (2) JP2007510621A (en)
KR (3) KR20060073584A (en)
CN (1) CN101123878A (en)
CA (1) CA2534342C (en)
WO (1) WO2005046575A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10097388B2 (en) 2017-08-16 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
KR20060073584A (en) * 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs
EP1709004A2 (en) 2003-12-29 2006-10-11 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
EP3363463A2 (en) * 2004-01-07 2018-08-22 Seikagaku Corporation Hyaluronic acid derivative and drug containing the same
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1978961B1 (en) 2006-01-06 2016-03-16 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
ES2555315T3 (en) 2006-03-31 2015-12-30 Sunovion Pharmaceuticals Inc. Preparation of amides and amines chiral
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7968595B2 (en) 2006-07-06 2011-06-28 Cytovia, Inc. Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
CN1907954B (en) * 2006-08-16 2011-11-23 重庆医科大学医药研究所 Water-soluble derivative of anesthetic 2,6-diisopropyl phenol and preparation method thereof
ES2509342T3 (en) 2006-10-30 2014-10-17 Chroma Therapeutics Limited Hydroxamates as histone deacetylase inhibitors
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR101581289B1 (en) 2007-05-31 2015-12-31 세프라코 아이엔시. Monoamine re-phenyl-substituted cycloalkyl amine as absorption inhibitor
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
EP2245012B1 (en) 2008-02-29 2013-07-03 Chroma Therapeutics Limited Inhibitors of p38 map kinase
CA2792224A1 (en) * 2008-12-15 2010-07-01 Proteus Digital Health, Inc. Body-associated receiver and method
WO2010071878A1 (en) 2008-12-19 2010-06-24 Pinnacle Pharmaceuticals, Inc. Phenazopyridine compounds
WO2010149760A3 (en) * 2009-06-24 2011-09-29 Shire Llc Mexiletine amino acid and peptide prodrugs and uses thereof
KR20120099462A (en) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 Spiro-oxindole mdm2 antagonists
CN101906039B (en) * 2010-06-23 2013-05-08 四川大学华西医院 Hydroxyl acid ester compound of substituted phenol, preparation method and application in drug
CA2813388A1 (en) 2010-10-06 2012-04-12 Laboratorios Senosiain S.A. De C.V. New salt of a pyrimidin derivative
KR20140027913A (en) 2010-11-12 2014-03-07 더 리젠츠 오브 더 유니버시티 오브 미시건 Spiro-oxindole mdm2 antagonists
US20120196933A1 (en) * 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
CA2835422C (en) 2011-05-11 2016-10-11 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
FR2976944A1 (en) 2011-06-21 2012-12-28 Centre Nat Rech Scient peptidic prodrug
EP2847197A4 (en) * 2012-05-07 2015-11-04 Cellix Bio Private Ltd Prodrugs of anti-platelet agents
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
EP2773378B1 (en) 2011-10-31 2016-08-10 Larsen, Claus Selch Prodrugs of non-steroid anti-inflammatory agents (nsaids)
US9624243B2 (en) 2012-01-06 2017-04-18 Novartis Ag Heterocyclic compounds and methods of their use
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A3 (en) 2012-05-10 2016-09-01 Cellixbio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A3 (en) 2012-05-10 2016-09-01 Cellixbio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013167997A3 (en) 2012-05-10 2016-09-01 Cellixbio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175359A3 (en) 2012-05-23 2014-02-20 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
CN104583182A (en) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 Compositions and methods for treatment of mucositis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A3 (en) 2012-05-23 2014-01-30 Mahesh Kandula Compositions and methods for treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2014020480A3 (en) 2012-08-03 2014-04-24 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
EP2888260B1 (en) * 2012-08-27 2018-08-22 Calitor Sciences, LLC Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2014037833A3 (en) 2012-09-06 2014-04-24 Mahesh Kandula Compositions and methods for treatment of inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
CN102924398B (en) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 A method for removing efavirenz diastereomers
CN103880754A (en) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 Alkaline amino acid ester salt of propofol
CN103263405B (en) * 2013-05-08 2015-04-22 南京医科大学 Medicinal composition for treating diabetes, and its application
CN103360240B (en) * 2013-07-23 2015-03-11 西安新通药物研究有限公司 Preparation method of high purity fenofibric acid
CN103951557B (en) * 2014-04-22 2016-06-08 徐州工业职业技术学院 The inorganic base is a kind of catalyst preparation method fenofibrate
US20170112892A1 (en) * 2014-05-30 2017-04-27 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
EP3240779A1 (en) 2014-09-26 2017-11-08 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (en) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 Compositions and methods for the treatment of multiple sclerosis
CN107108535A (en) 2014-10-27 2017-08-29 塞尔利克斯生物私人有限公司 Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US20160120838A1 (en) 2014-11-05 2016-05-05 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN104628554A (en) * 2015-02-09 2015-05-20 徐州工程学院 Fenofibric acid crystal form and preparation method thereof
CN105037180B (en) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 Central analgesic novel compounds, preparation and use of a dual action
WO2017193562A1 (en) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 Water soluble rapamycin derivative
CN106316921A (en) * 2016-08-19 2017-01-11 河南东泰制药有限公司 Preparation method for acemetacin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5432183A (en) * 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH1143467A (en) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk Fatty acid glyceride derivative and glyceride derivative, and their production
JP2001510810A (en) * 1997-07-23 2001-08-07 サエトネ、マルコ ファブリジオ Methods for solubilizing the formulation active ingredient in water or aqueous vehicles
JP2004517045A (en) * 2000-08-18 2004-06-10 アドバンスト ライフ サイエンシーズ インコーポレイテッド Prodrugs of a therapeutic betulinic acid derivatives of cancer and hiv
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
DE602004014117D1 (en) * 2003-03-25 2008-07-10 Vertex Pharma Thiazoles for use as inhibitors of protein kinases
KR20060073584A (en) * 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5432183A (en) * 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1660017A4 *
YANG C. ET AL.: "Chemical Stability, Enzymatic Hydrolysis, and Nasal Uptake of Amino Acid Ester Prodrugs of Acyclovir", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 90, no. 5, pages 617 - 624, XP008112431 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10097388B2 (en) 2017-08-16 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping

Also Published As

Publication number Publication date Type
EP1660017A4 (en) 2011-03-09 application
CA2534342A1 (en) 2005-05-26 application
KR20060073584A (en) 2006-06-28 application
JP2013035863A (en) 2013-02-21 application
EP1660017A2 (en) 2006-05-31 application
KR20130081319A (en) 2013-07-16 application
CN101123878A (en) 2008-02-13 application
CA2534342C (en) 2016-05-10 grant
KR20120116991A (en) 2012-10-23 application
WO2005046575A2 (en) 2005-05-26 application
JP2007510621A (en) 2007-04-26 application

Similar Documents

Publication Publication Date Title
WO2008010963A3 (en) Immune response modifier formulations
WO2006079550A3 (en) Alcohol resistant dosage forms
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006015261A3 (en) Nucleoside phosphonate conjugates as anti hiv agents
WO2009005677A3 (en) Antiviral compounds
WO2004096234A3 (en) Kinase inhibitor phosphonate conjugates
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
WO2009080691A3 (en) Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2004073703B1 (en) Glycinamide derivative for inhibiting hiv replication
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2009001673A1 (en) Atp-containing immunoadjuvant
WO2008042688A3 (en) Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2007090393A3 (en) Microtablet-based pharmaceutical preparation
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007007151A3 (en) Use of anti-mad-cam antibody for the treatment of emphysema
WO2006099169A3 (en) Novel liposome compositions
CA2653941A1 (en) Substituted amino purine derivatives and uses thereof
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2004096285A3 (en) Anti-infective phosphonate conjugates

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200600660

Country of ref document: ZA

Ref document number: 2006/00660

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006522125

Country of ref document: JP

Ref document number: 11343557

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2534342

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067002214

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 942/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 545570

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004816791

Country of ref document: EP

Ref document number: 2004289174

Country of ref document: AU

REEP

Ref document number: 2004816791

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2004289174

Country of ref document: AU

Date of ref document: 20040729

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004289174

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004816791

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067002214

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11343557

Country of ref document: US